Want to see HK:2522 full AI Analyst Report?
2522 Stock Chart & Stats
HK$8.10
-HK$4.70(-9.29%)
At close: 4:00 PM EST
HK$8.10
-HK$4.70(-9.29%)
Day’s Range― - ―
52-Week RangeHK$3.74 - HK$24.44
Previous CloseN/A
Volume38.00K
Average Volume (3M)10.53M
Market Cap
HK$1.86B
Enterprise ValueHK$1.79B
Total Cash (Recent Filing)HK$626.16M
Total Debt (Recent Filing)HK$622.72M
Price to Earnings (P/E)381.1
Beta1.25
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding294,128,080
10 Day Avg. Volume6,254,929
30 Day Avg. Volume10,530,505
Financial Highlights & Ratios
PEG Ratio-6.51
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Return To ProfitabilityThe company’s 2025 return to revenue growth and a move from a large loss to a small profit indicates stabilization of core operations and demand. This recovery supports sustainable operating leverage, improves prospects for consistent cash generation, and underpins medium-term business viability.
Stronger Operating And Free Cash Flow In 2025A meaningful rebound in operating cash flow and a return to positive free cash flow show the business can convert earnings into spendable cash. That enhances ability to fund capex, service debt, and invest in growth initiatives over the next several quarters, strengthening financial resilience.
Manageable Balance Sheet LeverageA sizeable equity base versus debt provides a durable cushion against shocks and allows flexibility for funding and strategic moves. Manageable leverage supports creditworthiness and reduces bankruptcy risk, enabling the company to pursue investments without immediate solvency pressure.
Bears Say
Volatile Free Cash Flow HistoryWide swings in free cash flow driven by capex and working-capital variability reduce predictability of internal funding and shareholder returns. This volatility can constrain consistent reinvestment or deleveraging plans and increases execution risk over the next several quarters.
Inconsistent Profitability And Earnings QualitySharp swings in revenue and net income highlight inconsistent margins and earnings quality. A very thin 2025 profit after a large prior-year loss suggests results remain fragile and could reverse, complicating medium-term forecasting and capital allocation decisions.
Rising Debt Versus Prior YearAn upward trend in debt reduces financial flexibility and increases interest and refinancing risk, particularly if earnings remain uneven. Even with current leverage manageable, rising indebtedness can limit strategic options and pressure margins if cash generation falters.
Jiangxi Rimag Group Co., Ltd. Class H News
2522 FAQ
What was Jiangxi Rimag Group Co., Ltd. Class H’s price range in the past 12 months?
Jiangxi Rimag Group Co., Ltd. Class H lowest stock price was HK$3.74 and its highest was HK$24.44 in the past 12 months.
What is Jiangxi Rimag Group Co., Ltd. Class H’s market cap?
Jiangxi Rimag Group Co., Ltd. Class H’s market cap is HK$1.86B.
When is Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date?
Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 17 days.
How were Jiangxi Rimag Group Co., Ltd. Class H’s earnings last quarter?
Jiangxi Rimag Group Co., Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.036.
Is Jiangxi Rimag Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangxi Rimag Group Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangxi Rimag Group Co., Ltd. Class H pay dividends?
Jiangxi Rimag Group Co., Ltd. Class H does not currently pay dividends.
What is Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate?
Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangxi Rimag Group Co., Ltd. Class H have?
Jiangxi Rimag Group Co., Ltd. Class H has 294,128,080 shares outstanding.
What happened to Jiangxi Rimag Group Co., Ltd. Class H’s price movement after its last earnings report?
Jiangxi Rimag Group Co., Ltd. Class H reported an EPS of -HK$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.68%.
Which hedge fund is a major shareholder of Jiangxi Rimag Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2522
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangxi Rimag Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Jiangxi Rimag Group Co., Ltd. Class H
Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammography, serving both patients and other healthcare sector clients. It also offers sophisticated imaging solution services. Additionally, Rimag Cloud provides various digital offerings such as cloud-based storage and film modules, a cloud radiology information system (RIS), a cloud Picture Archive and Communication System (PACS), alongside modules for AI integration and operational management within imaging platforms. The firm also oversees and manages a medical imaging platform that hosts a diverse range of imaging-related services. Supporting its activities is a dedicated research and development center, and it further engages in the distribution of medical equipment and related consumables. Established in 2014, the company maintains its primary office in Beijing, China.
Technical Analysis
EuroEyes International Eye Clinic Limited
―
Chaoju Eye Care Holdings Ltd.
―
Yonghe Medical Group Co., Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―